5 documents

Read All
08:00 , Dec 17, 2012 |  BC Week In Review  |  Company News

Ferrer, Vivia Biotech deal

The companies partnered to co-develop Vivia009 to treat blood cancers, including non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Vivia used its drug repositioning platform to develop Vivia009, an undisclosed formulation of an undisclosed existing...
Read More
07:00 , Oct 15, 2012 |  BC Week In Review  |  Company News

Vivia Biotech management update

Vivia Biotech S.L. , Madrid, Spain   Business: Cancer, Endocrine/Metabolic, Autoimmune   Hired: Ferran Prat as COO of Vivia's personalized medicine division; formerly a VP of global marketing, corporate business development and global services at...
Read More
07:00 , Apr 23, 2012 |  BC Week In Review  |  Financial News

Vivia Biotech completes venture financing

Vivia Biotech S.L. , Madrid, Spain   Business: Cancer, Endocrine/Metabolic, Autoimmune   Date completed: 4/16/12   Type: Venture financing   Raised: €1.3 million ($1.6 million)   Investor: Bioanalitica Inversiones  ...
Read More
07:00 , Apr 23, 2012 |  BC Week In Review  |  Financial News

Vivia Biotech completes venture financing

Vivia Biotech S.L. , Madrid, Spain   Business: Cancer, Endocrine/Metabolic, Autoimmune   Date completed: 4/16/12   Type: Venture financing   Raised: €6 million ($7.8 million)   Investor: Multiinstrument JEREMIE Fund  ...
Read More
01:06 , Apr 17, 2012 |  BC Extra  |  Financial News

Vivia receives loans, equity totaling EUR 7.2 million

Cancer company Vivia Biotech S.L. (Madrid, Spain) received EUR 6 million ($7.8 million) in loans from the Multiinstrument JEREMIE Fund and a EUR 1.25 million ($1.6 million) equity investment from Bioanalitica Inversiones S.L. Vivia is...
Read More